A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms

European Journal of Vascular and Endovascular Surgery

Volumn 41, Issue 1, 2011, Pages 28-35

  Dawson, J A ^a   Choke, E ^a   Loftus, I M ^a   Cockerill, G W ^a   Thompson, M M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; Ezetimibe; Medical management; Randomised controlled trial; Statins

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGENASE 3; EZETIMIBE; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE ELASTASE; NEUTROPHIL COLLAGENASE; PLACEBO; SIMVASTATIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; AGED; ANEURYSM SURGERY; ANTIINFLAMMATORY ACTIVITY; AORTA WALL; ARTICLE; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTIVE SURGERY; ENDOVASCULAR SURGERY; EXPLANT; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; TISSUE HOMOGENATE; TISSUE LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AZETIDINES; BIOPSY; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKINS; LIPIDS; MALE; MATRIX METALLOPROTEINASES; PILOT PROJECTS; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650847349     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2010.08.023     Document Type: Article

References (52)

1. M.M. Thompson, and P.R.F. Bell Arterial aneurysms Br Med J 320 7243 2000 1193 1197
2. J. Dawson, E. Choke, S. Sayed, G. Cockerill, I. Loftus, and M.M. Thompson Pharmacotherapy of abdominal aortic aneurysms Curr Vasc Pharmacol 4 2 2006 129 149
3. J. Golledge, and J.T. Powell Medical management of abdominal aortic aneurysm Eur J Vasc Endovasc Surg 34 3 2007 267 273 (Pubitemid 47194418)
4. J. Evans, J.T. Powell, E. Schwalbe, I.M. Loftus, and M.M. Thompson Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue Eur J Vasc Endovasc Surg 34 3 2007 302 303
5. J. Golledge, J. Muller, A. Daugherty, and P. Norman Abdominal aortic aneurysm: pathogenesis and implications for management Arterioscler Thromb Vasc Biol 26 12 2006 2605 2613
6. H.E. Bays, L. Ose, N. Fraser, D.L. Tribble, K. Quinto, and R. Reyes A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia Clin Ther 26 11 2004 1758 1773
7. J.A. Curci, S. Liao, M.D. Huffman, S.D. Shapiro, and R.W. Thompson Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms J Clin Invest 102 11 1998 1900 1910
8. N. Vine, and J.T. Powell Metalloproteinases in degenerative aortic disease Clin Sci (Lond) 81 2 1991 233 239
9. I.J. Franklin, L.J. Walton, R.M. Greenhalgh, and J.T. Powell The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta Eur J Vasc Endovasc Surg 18 1 1999 35 42
10. W.R. Wilson, J. Evans, P.R. Bell, and M.M. Thompson HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms Eur J Vasc Endovasc Surg 30 3 2005 259 262
11. J. Dawson, G.W. Cockerill, E. Choke, A.M. Belli, I. Loftus, and M.M. Thompson Aortic aneurysms secrete interleukin-6 into the circulation J Vasc Surg 45 2 2007 350 356
12. C.P. Sparrow, C.A. Burton, M. Hernandez, S. Mundt, H. Hassing, and S. Patel Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering Arterioscler Thromb Vasc Biol 21 1 2001 115 121
13. M. Ortego, C. Bustos, M.A. Hernandez-Presa, J. Tunon, C. Diaz, and G. Hernandez Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells Atherosclerosis 147 2 1999 253 261
14. A. Rezaie-Majd, T. Maca, R. Bucek, P. Valent, M. Muller, and P. Husslein Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients Arterioscler Thromb Vasc Biol 22 2002 1194 1199
15. U. Schonbeck, and P. Libby Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 21 Suppl. 1 2004 1118 1126
16. M. Jasinska, J. Owczarek, and D. Orszulak-Michalak Statins: a new insight into their mechanisms of action and consequent pleiotropic effects Pharmacol Rep 59 5 2007 483 499
17. A. Kalyanasundaram, J.R. Elmore, J.R. Manazer, A. Golden, D.P. Franklin, and S.W. Galt Simvastatin suppresses experimental aortic aneurysm expansion J Vasc Surg 43 1 2006 117 124
18. S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, and R. Paoletti HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages Arterioscler Thromb Vasc Biol 18 11 1998 1671 1678
19. M. Aikawa, E. Rabkin, S. Sugiyama, S.J. Voglic, Y. Fukumoto, and Y. Furukawa An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro Circulation 103 2 2001 276 283
20. F. Ganné, M. Vasse, J.-L. Beaudeux, J. Peynet, A. Francois, and Z. Mishal Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherosclerosis Thromb Haemost 84 4 2000 680 688
21. I.K. Wang, S.Y. Lin-Shiau, and J.K. Lin Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology 59 2000 245 254
22. K.E. Porter, J. Naik, N.A. Turner, T. Dickinson, M.M. Thompson, and N.J. London Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration J Vasc Surg 36 2002 150 157
23. Z. Luan, A.J. Chase, and A.C. Newby Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 form vascular smooth muscle cells and macrophages Arterioscler Thromb Vasc Biol 23 2003 769 775
24. S. Abisi, K.G. Burnand, J. Humphries, M. Waltham, P. Taylor, and A. Smith Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms Br J Surg 2007
25. H. Nagashima, Y. Aoka, Y. Sakomura, A. Sakuta, S. Aomi, and N. Ishizuka A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall J Vasc Surg 36 1 2002 158 163
26. E.F. Steinmetz, C. Buckley, M.L. Shames, T.L. Ennis, S.J. Vanvickle-Chavez, and D. Mao Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice Ann Surg 241 1 2005 92 101 (Pubitemid 40040997)
27. O. Schouten, J.H. van Laanen, E. Boersma, R. Vidakovic, H.H. Feringa, and M. Dunkelgrun Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth Eur J Vasc Endovasc Surg 32 1 2006 21 26
28. M. Mosorin, E. Niemela, J. Heikkinen, J. Lahtinen, V. Tiozzo, and J. Satta The use of statins and fate of small abdominal aortic aneurysms Interact Cardiovasc Thorac Surg 2008
29. R. Sukhija, W.S. Aronow, R. Sandhu, P. Kakar, and S. Babu Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins Am J Cardiol 97 2 2006 279 280
30. I. Guessous, D. Periard, D. Lorenzetti, J. Cornuz, and W.A. Ghali The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis PLoS ONE 3 3 2008 e1895
31. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
32. G. Feussner HMG CoA reductase inhibitors Curr Opin Lipidol 5 1 1994 59 68
33. A. Corsini, N. Ferri, and M. Cortellaro Are pleiotropic effects of statins real? Vasc Health Risk Manag 3 5 2007 611 613
34. M.H. Davidson Clinical significance of statin pleiotropic effects: hypotheses versus evidence Circulation 111 18 2005 2280 2281
35. U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, and S. Schulz Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans Circulation 111 18 2005 2356 2363
36. J.P. Halcox, and J.E. Deanfield Beyond the laboratory: clinical implications for statin pleiotropy Circulation 109 21 Suppl. 1 2004 II42 II48
37. D. Li, R. Singh, L. Liu, H. Chen, B. Singh, and N. Kazzaz Oxidised-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells Cardiovasc Res 57 2003 238 243 (Pubitemid 36009456)
38. C.Y. Wang, P.Y. Liu, and J.K. Liao Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol Med 14 1 2008 37 44
39. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler Thromb Vasc Biol 21 11 2001 1712 1719
40. A.S. Wierzbicki, R. Poston, and A. Ferro The lipid and non-lipid effects of statins Pharmacol Ther 99 1 2003 95 112
41. P.T. Sager, L. Melani, L. Lipka, J. Strony, B. Yang, and R. Suresh Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein Am J Cardiol 92 2003 1414 1418
42. F.A. Lederle, G.R. Johnson, S.E. Wilson, E.P. Chute, F.N. Littooy, and D. Bandyk Prevalence and associations of abdominal aortic aneurysm detected through screening Ann Intern Med 126 6 1997 441 449 Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group
43. H.G. Alcorn, S.K. Wolfson Jr., K. Sutton-Tyrrell, L.H. Kuller, and D. O'Leary Risk factors for abdominal aortic aneurysms in older adults enrolled in the cardiovascular health study Arterioscler Thromb Vasc Biol 16 8 1996 963 970
44. H.J. Pleumeekers, A.W. Hoes, E. van der Does, H. van Urk, A. Hofman, and P.T. de Jong Aneurysms of the abdominal aorta in older adults. The Rotterdam Study Am J Epidemiol 142 12 1995 1291 1299
45. S.D. Hobbs, M.W. Claridge, C.R. Quick, N.E. Day, A.W. Bradbury, and A.B. Wilmink LDL cholesterol is associated with small abdominal aortic aneurysms Eur J Vasc Endovasc Surg 26 6 2003 618 622
46. K. Singh, K.H. Bonaa, B.K. Jacobsen, L. Bjork, and S. Solberg Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromso Study Am J Epidemiol 154 3 2001 236 244
47. G. Simoni, C. Pastorino, R. Perrone, A. Ardia, R. Gianrossi, and F. Decian Screening for abdominal aortic aneurysms and associated risk factors in a general population Eur J Vasc Endovasc Surg 10 2 1995 207 210
48. C. Iribarren, J.A. Darbinian, A.S. Go, B.H. Fireman, C.D. Lee, and D.P. Grey Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study Ann Epidemiol 17 9 2007 669 678
49. M.E. Tornwall, J. Virtamo, J.K. Haukka, D. Albanes, and J.K. Huttunen Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers Epidemiology 12 1 2001 94 100
50. M.B. Rodin, M.L. Daviglus, G.C. Wong, K. Liu, D.B. Garside, and P. Greenland Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age Hypertension 42 1 2003 61 68 (Pubitemid 36842237)
51. B. Lindblad, G. Borner, and A. Gottsater Factors associated with development of large abdominal aortic aneurysm in middle-aged men Eur J Vasc Endovasc Surg 30 4 2005 346 352
52. J.K. Plenge, T.L. Hernandez, K.M. Weil, P. Poirier, G.K. Grunwald, and S.M. Marcovina Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation 106 12 2002 1447 1452